Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain
MWN-AI** Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently unveiled encouraging initial results from the first cohort of its Phase 1/2 clinical trial for CELZ-201-DDT, a stem cell-based therapy aimed at treating chronic back pain due to degenerative disc disease (DDD). Conducted with 10 participants—eight receiving the experimental treatment and two receiving a placebo—the trial has reported no serious adverse events or dose-limiting toxicities among those treated.
The independent Data Safety Monitoring Board (DSMB) thoroughly reviewed the data and endorsed proceeding to the next cohort of the trial, reinforcing the treatment's safety and the study's integrity. Preliminary findings indicate potential therapeutic benefits, showing promise in alleviating chronic back pain and restoring functional capabilities in participants.
Timothy Warbington, President and CEO of Creative Medical Technology Holdings, emphasized the company's commitment to addressing chronic back pain, a condition affecting millions, with limited effective treatment options. With the safety profile confirmed and early efficacy signals emerging, the organization is preparing for enrollment of the next cohort in early 2025.
CELZ-201-DDT presents a unique, non-opioid therapeutic option administered via an ultrasound-guided, non-surgical injection. This method targets and potentially repairs the underlying issues associated with DDD, improving blood supply around affected discs without the radiation exposure linked to some cell-based treatments.
Creative Medical Technology Holdings is at the forefront of regenerative medicine, dedicated to developing innovative therapies that enhance patients’ quality of life. The positive progression of the CELZ-201-DDT study underscores their mission to revolutionize treatment approaches for chronic conditions and improve outcomes for those enduring debilitating pain.
MWN-AI** Analysis
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) recently announced positive preliminary results from the Phase 1/2 trial of its stem cell-based therapy, CELZ-201-DDT, for treating chronic back pain linked to degenerative disc disease (DDD). With no serious adverse events reported and early efficacy signals observed, this development is significant for both the company and the broader healthcare landscape.
Investors may find this news particularly strategic, as it positions CELZ as a potential leader in addressing a sizable market characterized by unmet medical needs. Chronic back pain afflicts millions, and current treatment options remain limited, often relying on opioids with adverse side effects. With an innovative solution that targets the underlying causes of DDD through non-surgical methods, CELZ-201-DDT could differentiate itself, attracting a shift in patient preference toward regenerative therapies.
The endorsement from the independent Data Safety Monitoring Board (DSMB) for trial progression reinforces confidence in the treatment’s safety and the study's integrity. As enrollment for the next cohort is expected in Q1 2025, and with a robust pipeline for future innovation, the momentum could enhance CELZ’s stock valuation in the biotechnology market.
From a market perspective, investors should consider potential volatility leading up to subsequent trial results. While the biotechnology sector often experiences fluctuations based on clinical trial outcomes, the encouraging initial results present a compelling investment opportunity. Risk-averse investors may wish to adopt a cautious approach, while those with a higher risk tolerance could capitalize on current pricing.
As CELZ progresses, maintaining an eye on clinical trial milestones and market sentiment will be crucial. The company’s focus on innovative regenerative solutions positions it well for future growth, creating an intriguing narrative for investors in the biotechnology field.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a clinical-stage biotechnology company focused on regenerative medicine, today announced promising initial data from the first cohort of its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, the Company’s proprietary stem cell-based therapeutic for the treatment of chronic back pain caused by degenerative disc disease (DDD).
The first cohort of 10 participants (8 receiving CELZ-201-DDT and 2 receiving placebo) completed the study phase without any dose-limiting toxicities or serious adverse events. Blinded preliminary data suggest encouraging therapeutic potential in alleviating back pain and restoring functionality. Following a comprehensive safety review, the independent Data Safety Monitoring Board (DSMB) recommended the trial proceed to the next cohort as planned.
Key Milestones Achieved:
- Safety Confirmed: CELZ-201-DDT demonstrated an excellent safety profile, with no serious adverse events reported in the first cohort.
- Preliminary Efficacy Signals: Blinded data suggest potential therapeutic benefit in addressing chronic back pain associated with degenerative disc disease.
- DSMB Endorsement: The DSMB approved continuation of the study, validating the safety and integrity of the trial design.
- Next Steps: Enrollment for the second cohort is expected in the current first quarter of 2025, with comprehensive data from subsequent cohorts guiding future clinical and regulatory plans.
“This milestone underscores our commitment to addressing chronic back pain, a debilitating condition with limited effective treatment options,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “The safety and early signals observed in this trial strengthen our belief that CELZ-201-DDT has the potential to transform the standard of care for patients suffering from degenerative disc disease.”
Advancing Innovation in Regenerative Medicine
Creative Medical Technology Holdings is committed to pioneering regenerative solutions that improve quality of life for patients with chronic and debilitating conditions. CELZ-201-DDT represents the Company’s dedication to leveraging stem cell technology to address the root causes of pain and degenerative conditions, providing patients with a novel, non-opioid therapeutic option.
“Our progress with CELZ-201-DDT highlights our vision to deliver groundbreaking therapies for chronic conditions such as degenerative disc disease,” added Warbington. “We are eager to move forward with the trial and are optimistic about the therapy’s ability to provide long-lasting pain relief and improved functionality for patients.”
About CELZ-201-DDT
CELZ-201-DDT is a proprietary regenerative stem cell-based therapy designed to address chronic back pain caused by DDD. By targeting the underlying causes of DDD, CELZ-201-DDT has the potential to restore disc integrity and reduce pain, providing a novel therapeutic approach to a condition that affects millions of patients. Using an ultrasound guided, non-surgical procedure CELZ-201-DDT is injected in areas surrounding the diseased disc(s), thereby potentially repairing, remodeling, and improving the blood supply around the disc and lower back area, without exposing the patient to radiation as with other cell-based procedures.
The Phase 1 / 2 study is designed to evaluate the safety, efficacy, and tolerability of CELZ-201-DDT. The study will enroll 30 individuals suffering from chronic lower back pain.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology company focused on developing regenerative and stem cell-based therapies for unmet medical needs. Leveraging its proprietary platforms, the Company is advancing a robust pipeline of innovative treatments to improve patient outcomes and revolutionize regenerative medicine. For more information, visit www.creativemedicaltechnology.com .
Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect the Company’s current views but are not guarantees of future results.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
FAQ**
What specific findings have emerged from the Phase 1/2 trial of Creative Medical Technology Holdings Inc. CELZ-201-DDT that support its potential effectiveness in treating chronic back pain caused by degenerative disc disease?
How does Creative Medical Technology Holdings Inc. CELZ-201-DDT differentiate itself from existing treatments for degenerative disc disease, particularly in terms of safety and therapeutic approach?
What are the key criteria for enrolling participants in the next cohort of Creative Medical Technology Holdings Inc. CELZ-201-DDT’s clinical trial, and how many patients are expected to be involved in the study?
Given the promising initial results reported by Creative Medical Technology Holdings Inc. CELZ, what are the planned next steps for the regulatory pathway and future development of CELZ-201-DDT going forward?
**MWN-AI FAQ is based on asking OpenAI questions about Creative Medical Technology Holdings Inc. (NASDAQ: CELZ).
NASDAQ: CELZ
CELZ Trading
3.38% G/L:
$1.99 Last:
5,542 Volume:
$1.945 Open:
